RECRUITING Phase 2 ClinicalTrials.gov

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Sponsor: Ryvu Therapeutics SA • ClinicalTrials.gov ID: NCT06191263

Registry updated: 2026-09-18

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2

Interventions

RVU120 (Drug)
RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Venetoclax (Drug)
Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis

Eligibility criteria

Inclusion Criteria: * Patients must have a diagnosis of AML (per 2022 WHO classification) * Patients must have relapsed or refractory AML (per ELN 2022 criteria) * Patients must have failed first-line treatment with venetoclax combined with a hypomethylating agent * Patients must have no alternative therapeutic options likely to produce clinical benefit * Patients must have ECOG performance status of 0 to 2 * Patients must have adequate end organ function defined as: 1. WBC \< 25 x 10(9)/L on Day 1 prior to first dose of study drug 2. Platelet count \> 10,000/mcL on Day 1 prior to first dose of study drug 3. AST (aspartate transaminase) and ALT (alanine transaminase) ≤ 3 x ULN (upper limit of normal) 4. Total bilirubin ≤ 3 x ULN 5. Creatinine clearance (Cockcroft \& Gault formula) ≥ 50 mL/min 6. LVEF (left ventricular ejection fraction) ≥ 40% by electrocardiography * Subjects must have the ability to understand and the willingness to sign a written informed consent document and complete study related procedures Exclusion Criteria: * APL (acute promyelocytic leukemia), the M3 subtype of AML * Active CNS (central nervous system) leukemia * Previous treatment with CDK8 and/or CDK19-targeted therapy * Major surgery within 28 days prior to the first dose of study drug * Hematopoietic stem cell transplant within 120 days prior to the first dose of study drug * Currently pregnant or breast-feeding. Females of child bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug * Uncontrolled intercurrent illness that could limit life expectancy or ability to complete study correlates. This includes but is not limited to: 1. Active, Grade ≥2 acute GVHD (graft versus host disease) or requirement for systemic immunosuppressive medication for GVHD 2. Evidence of ongoing or uncontrolled systemic bacterial, fungal or viral infection and acute inflammatory conditions (including pancreatitis) 3. Ongoing significant liver disease such as cirrhosis, drug-induced liver injury, active hepatitis, or chronic persistent hepatitis B and/or hepatitis C 4. Ongoing drug-induced pneumonitis 5. Significant cardiac dysfunction, defined as myocardial infarction within 12 months prior to the first dose of study drug, NYHA (New York Heart Association) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina 6. History of ventricular arrhythmia or QTc ≥ 470 ms (Bazett's formula) 7. Prior history of malignancies other than AML, unless disease-free for 5 years or more or prior basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, carcinoma in situ of cervix, breast or bladder, and incidental histological finding of prostate cancer (TMN stage T1a or T1b) * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RVU120 and/or venetoclax * Taking any medications, herbal supplements, or other substances (including smoking( that are known to be strong inhibitors or moderate/strong inducers or sensitive substrates of CYP1A2 * Taking any medications, over-the-counter medications, foods or herbal supplements that are known to be strong or moderate inhibitors of CYP3A4 or P-gp (P-glycoprotein) * Known allergy or hypersensitivity to any component of RVU120 or venetoclax formulations

Conditions

Acute Myeloid Leukemia

Locations

Centre Hospitalier Universitaire Grenoble Alpes — Grenoble, France
Centre Hospitalier Le Mans — Le Mans, France
Centre Hospitalier Universitaire De Lille — Lille, France
Institut Paoli-Calmettes — Marseille, France
Centre Hospitalier Universitaire De Nice — Nice, France
Centre Hospitalier Universitaire De Nimes — Nîmes, France
Assistance Publique Hopitaux De Paris — Paris, France
Centre Henri Becquerel — Rouen, France
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola, Forlì-Cesena, Italy
Azienda Ospedaliero Universitaria Delle Marche — Ancona, Italy
Univerisity of Bologna Policlinico Sant'Orsola — Bologna, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia — Brescia, Italy
Ospedale Vito Fazzi Lecce — Lecce, Italy
AUSL Romagna - Ospedale S.M. Delle Croci — Ravenna, Italy
Azienda Ospedaliera Policlinico Universitario Tor Vergata — Roma, Italy
Istituto Clinico Humanitas — Rozzano, Italy
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino — Turin, Italy
MTZ Clinical Research — Warsaw, Mazowieckie Województwo, Poland
Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej — Biała Podlaska, Poland
Uniwersyteckie Centrum Kliniczne — Gdansk, Poland
PRATIA Onkologia Katowice — Katowice, Poland
Wojewodzki Szpital Zespolony Im.L.Rydygiera w Toruniu — Torun, Poland
Instytut Hematologii i Transfuzjologii — Warsaw, Poland
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy — Warsaw, Poland
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego — Wałbrzych, Poland
Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii — Wroclaw, Poland
Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o. — Zielona Góra, Poland
Hospital Del Mar — Barcelona, Spain
Hospital De La Santa Creu I Sant Pau — Barcelona, Spain
Institut Catala D'oncologia — Barcelona, Spain
Hospital San Pedro De Alcantara — Cáceres, Spain
MD Anderson Cancer Center — Madrid, Spain
Hospital Universitario La Paz — Madrid, Spain
Hospital Universitario Regional De Malaga — Málaga, Spain
Clinica Universidad De Navarra — Pamplona, Spain
University Hospital Virgen Del Rocio S.L. — Seville, Spain
Hospital Universitario Y Politecnico La Fe — Valencia, Spain

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment